Novo Nordisk's Oral Wegovy Shows Greatest Weight Loss in Patients with Recent Weight Gain
A recent observational study found that individuals who had not previously used GLP-1 medications and experienced weight gain within the last few years achieved the most significant weight loss when starting Novo Nordisk’s oral Wegovy (semaglutide). The findings suggest that patients newer to obesity or those with more recent onset may respond better to this treatment. This real-world data could influence prescribing patterns, as it highlights a potential subgroup of patients who benefit most from the drug. The results add context for healthcare providers and investors evaluating Wegovy’s market performance and long-term adoption in treating obesity. Novo Nordisk has seen strong demand for its GLP-1 drugs like Ozempic and Wegovy amid growing interest in weight management therapies.
Tickers: $NVO
Topics: GLP-1 medications real-world data Wegovy (semaglutide) weight loss